ArticleNutrition & metabolism2026
Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveSystematic evaluation of the efficacy and safety of lower-carbohydrate dietary patterns (LCDP) in metabolic associated fatty liver disease (MAFLD).
methodsThe literature search was conducted in 8 databases, covering all relevant randomized controlled trials on LCDP intervention for MAFLD patients from the database establishment to June 1, 2025. The quality of the literature was evaluated using the Cochrane Bias Risk Assessment Tool. The extracted data were analyzed using Review Manager 5.3 software for meta-analysis. Sensitivity analysis and publication bias detection were performed using Stata 18.0 software.
resultsThe study included 9 randomized controlled trials (RCTs) that met the criteria, involving 408 MAFLD patients and covering 18 outcome measures related to anthropometry, liver function, blood pressure, blood lipids, and blood glucose. The study results indicate that LCDP can significantly affect the body weight (BW) and its 95% confidence intervals (CI) is -4.09 kg[-7.36, -0.81]; waist circumference (WC) -4.84 cm[-5.46, -4.23]; body mass index (BMI) -1.60 kg/m
conclusionLCDP can improve obesity and insulin resistance (IR) in MAFLD patients, and has a layered mechanism for regulating blood pressure. Its short-term effects on liver enzymes, visceral organs, and liver fat are limited, high saturated fat may weaken its effect on improving serum cholesterol.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.